$WAT

Waters Corporation (NYSE: WAT) launched AI-Powered Peak Integration for its Empower Software, aiming to reduce manual interventions by 95% and improve accuracy by 76% in chromatography data processing. The feature is part of a strategy to integrate AI, ML, and automation into regulated workflows, with a pilot showing significant efficiency gains. The premium subscription service will be available in mid-2027, following a strategy that includes AI/ML Anomaly Detection launched in 2025.

Waters Corporation (WAT) announced AI-powered peak integration for its Empower Software, reducing manual interventions in chromatography data processing by up to 95% and improving accuracy by 76%. The feature, part of a premium subscription, is set for early access in December 2026 and full deployment in mid-2027. The company aims to advance Empower Software into a connected, intelligent platform for regulated science, with a growing portfolio of AI capabilities.

Danaher partnered with NVIDIA to advance AI-driven autonomous science, combining their technologies for faster research. Rush and Endeavor Health plan to merge, creating a large academic health system. FedEx Europe launched a digital portal for managing temperature-controlled pharmaceutical shipments. Waters Corporation introduced AI Link to connect AI with lab instruments, streamlining research processes.

Labcorp (LH) and Waters Corporation (WAT) partner to expand access to the FDA-approved BD Onclarity HPV Assay for cervical cancer screening, starting late 2026. The test supports all ASCCP guidelines and offers extended genotyping. Labcorp will provide testing through its nationwide network, aiming to address screening gaps and improve access for patients.

Quest Diagnostics and Waters Corporation plan to expand access to the Onclarity Self-Collection Kit for cervical cancer screening in 2027. The kit, used with the BD Onclarity HPV Assay, allows at-home sample collection and provides comprehensive genotyping. Quest, serving half of U.S. physicians, will distribute the kit through its clinician, health plan, and consumer channels.

Waters Corporation launched Waters AI Link, integrating Anthropic’s AI models with its laboratory instruments. The software allows scientists to use natural language to manage workflows, aiming to reduce manual intervention and accelerate research. AI Link is available in an early-access program, with general availability planned for November 2026. Waters also joined Anthropic’s Model Hardware Standard research program to enhance AI-agent interaction with lab equipment.

Healthcare sector is gaining momentum as investors rotate out of AI stocks. Analysts highlight Waters Corp. (WAT) and Thermo Fisher Scientific (TMO) as key players in life science tools. WAT reported Q2 earnings with revenue of $1.65B and EPS of $3.05, raising full-year guidance. TMO reported Q2 revenue of $11.99B and EPS of $6.03, with multiple analysts raising price targets. Both companies are set to report Q3 earnings soon.

Waters Corporation launched Waters AI Link, integrating Anthropic's Model Context Protocol (MCP) into its waters_connect platform. This allows scientists to control LC-MS instruments via AI, reducing integration time from weeks to hours. The system ensures compliance with FDA-EMA good AI practices and is set for general availability in November 2026. Waters AI Link enables seamless data transfer and automation, potentially speeding up research and quality control processes.

Argus raised its target price for Tenet Healthcare (THC) to $294.00. The company operates 47 hospitals and over 500 outpatient facilities in the US, mainly in the South. This update may impact investor sentiment and trading activity for THC.

JPMorgan raised its price target for Waters Corporation to $435 from $400. The company recently launched Waters AI Link, a new product. Waters' stock is currently trading at $429.17, with a 5-day change of -0.68% and a year-to-date change of +12.99%.